Spectral Medical Inc.

Equities

EDT

CA8475771033

Pharmaceuticals

Market Closed - Toronto S.E. 03:59:47 2024-04-19 pm EDT 5-day change 1st Jan Change
0.44 CAD 0.00% Intraday chart for Spectral Medical Inc. 0.00% +3.53%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Spectral Medical Updated on Tigris Trial MT
Spectral Medical Brief: Providing Tigris Trial Update; 101 patients enrolled MT
Spectral Medical Provides Tigris Trial Update CI
North American Morning Briefing : Investors on -2- DJ
Spectral Medical Brief: Paul Walker will immediately succeed Bihl as Chair MT
Spectral Medical Brief: Anthony Bihl III, Spectral's Chairman, will be retiring from the Board at Upcoming Shareholder Meeting in June 2024 MT
Spectral Medical Inc. Announces Board Changes CI
Spectral Medical Brief: Says Total of 97 patients randomized to date out of the 150 total patients to be enrolled in the Tigris trial MT
Spectral Medical Brief: Q4 Revenue $365,000; Loss was $6,479,000, or $0.02 per share MT
Spectral Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Struggle After New Records DJ
Spectral Medical Provides February Tigris Trial Update MT
Spectral Medical Inc. Provides Update on the Company's Tigris Trial CI
Spectral Medical Brief: Providing February Tigris Trial Update; 93 patients enrolled; February represents a second record breaking consecutive month for patient enrollment MT
Transcript : Spectral Medical Inc. - Special Call
Spectral Medical Says PMX Distribution and Supply Agreement with Baxter International Extended for 10 Years MT
Spectral Medical Brief: Baxter to act as Exclusive partner to Spectral for 10 years following PMX approval by U.S. FDA MT
Spectral Medical Brief: Announcing Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation MT
Spectral Medical Inc. Announces Amendment and Extension of Exclusive Supply and Distribution Agreement with Baxter Healthcare Corporation CI
Spectral Medical Announcing "Major Milestone" by Reaching Its Interim Enrollment Target of 90 Patients MT
Spectral Medical Brief: Announcing "Major Milestone" by Reaching Its Interim Enrollment Target of 90 Patients MT
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients CI
Spectral Medical Provides Early February Tigris Trial Update MT
Spectral Medical Inc. Provides Early February Tigris Trial Update CI
Spectral Medical Provides January Tigris Trial Update MT
Chart Spectral Medical Inc.
More charts
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX has been on the market in many countries outside the United States and has been used in more than 340,000 patients to date. It is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. It is also continuing its legacy business of manufacturing and selling certain reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.44 CAD
Average target price
1.8 CAD
Spread / Average Target
+309.09%
Consensus
  1. Stock Market
  2. Equities
  3. EDT Stock
  4. News Spectral Medical Inc.
  5. Spectral Medical Says PMX Distribution and Supply Agreement with Baxter International Extended for 10 Years